17 research outputs found
INFLUENCE OF PROBIOTICS ON CYTOKINE PRODUCTION IN THE IN VITRO AND IN VIVO SYSTEMS
Modulatory effects of three probiotic bacterial strains (Lactobacillus rhamnosus K32 (L), Bifidobacterium longum GT15 (B, Enterococcus faecium L-3 (E) on expression level and contents of key cytokines were studied using PCR techniques with reverse transcription, and enzyme-linked immunosorbent assay. Both cell cultures and an experimental model of intestinal dysbiosis were used in this study.The genes encoding bacteriocins, surface membrane component, pili and exopolysaccharides involved in host immune system modulation were previously identified in the B and Ebacterial strains.Investigation of probiotic strains and effects of their supernatants expression of cytokines in cell cultures of promonocyte origin (HTP-1) showed increased expression of TNFΞ±, due to E and L supernatants. Moreover, the Bl culture induced IL-8 and IL-10 expression.In a model of Wistar rats with ampicillinand metronidazole-induced intestinal dysbiosis corrected with probiotics we have shown that the dysbiosis was accompanied by sufficient alterations in microbiota composition (Klebsiella spp. overgrowth and low contents of Faecalobacterium prausnitzii) that were observed only in the animals untreated with probiotics (control), or after administration of L.In contrast to these results, the animals treated with E and B, the following changes were revealed: 1) low expression of proinflammatory cytokines IL-8, TNFΞ±, MCP-1 inmesenteric lymph nodes and appropriate changes of their serum contents, 2) increased serum content of the anti-inflammatory TGFΞ² cytokine. Hence, the present study, having used two complementary models, has detected some individual features of immune modulation produced by the probiotictic strains of L. rhamnosus K32, B. longum GT15 ΠΈ E. faecium L-3 which exert differential effects upon the intestinal microbiota
Evaluation of probiotic lactobacillus as adjuvants for nasal immunization with chimeric pneumococcal vaccine
Vaccine protection against photogenic gram-positive bacteria including different species ofstreptococci is an important problem of contemporary molecular biology. Streptococcal infections are mostcommon bacterial infections surpassing by the economic losses all the infections excluding influenza. The gatesof streptococcal infection, oral cavity or vagina, are covered with immune and non-immune mucosal cells thatare the first line of defenses. Subcutaneous immunization not always stimulate the local immunity on mucosalsurfaces. On the other hand, mucosal vaccination can provide an appropriate local immune response togetherwith systemic protection. However, mucosal immunization often requires usage of special and effectiveadjuvants especially in case of vaccines based on recombinant proteins.For protection against Streptococcus pneumoniae infection, two chimeric recombinant proteins (PSPF andPSP) have been tested as vaccines. Recombinant proteins PSPF and PSP carry immunogenic epitopes fromthe respiratory pathogen including PspA, Spr1875 and PsaA. PSPF structure also carries a fraction of flagellin-FliC molecule in comparison with PSP, which does not have this fragment. This portion of PSPF was includedas internal adjuvant intended for the stimulation of Toll-like receptor 5.In this work, the adjuvant capacity of two probiotic strains, Lactobacillus rhamnosus CRL1505 andL. rhamnosus L32 was evaluated. It was demonstrated that both lactic acid bacteria strains were able to provideadjuvant effects by enhancing the mucosal and systemic immune responses after their co-administration withthe recombinant chimeric protein PSPF. The adjuvant effect of both Lactobacillus strains was significantlydecreased after their thermal inactivation. However, the cell walls of bacteria showed a marked adjuvant activity.An improved protection against several S. pneumoniae serotypes after mucosal immunization of infant micewith PSPF vaccine with probiotic strains or their cell walls was also demonstrated here.The recombinant chimeric protein PSPF administered with immunomodulatory probiotic strains or theirbacterial components would be a promising vaccine for immunization of humans against S. pneumoniae,particularly in children.ΠΠ΄Π½ΠΎΠΉ ΠΈΠ· Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΡ
Π·Π°Π΄Π°Ρ ΠΌΠ΅Π΄ΠΈΠΊΠΎ-Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π°ΡΠΊΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠΎΠ·Π΄Π°Π½ΠΈΠ΅ Π²Π°ΠΊΡΠΈΠ½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΏΡΠΎΡΠΈΠ² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π½ΡΡ
ΡΡΡΠ΅ΠΏΡΠΎΠΊΠΎΠΊΠΊΠΎΠ² β ΡΠ°ΠΌΡΡ
ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΡ
Π±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»Ρ-Π½ΡΡ
Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Π΅ΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°, ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΠ΅ΡΠ± ΠΎΡ ΠΊΠΎΡΠΎΡΡΡ
ΡΡΡΡΠΏΠ°Π΅Ρ Π»ΠΈΡΡ ΠΏΠΎΡΠ΅ΡΡΠΌ ΠΎΡ Π³ΡΠΈΠΏΠΏΠΎΠ·Π½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ. ΠΡ
ΠΎΠ΄Π½ΡΠΌΠΈ Π²ΠΎΡΠΎΡΠ°ΠΌΠΈ ΡΡΡΠ΅ΠΏΡΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΡΠ²Π»ΡΡΡΡΡ ΡΠ»ΠΈΠ·ΠΈΡΡΡΠ΅ ΠΎΠ±ΠΎ-Π»ΠΎΡΠΊΠΈ ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΈ ΠΌΠΎΡΠ΅ΠΏΠΎΠ»ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠ°ΠΊΡΠ°.
ΠΠ°ΡΠ΅Π½ΡΠ΅ΡΠ°Π»ΡΠ½ΡΠΉ ΡΠΏΠΎΡΠΎΠ± Π²Π²Π΅Π΄Π΅Π½ΠΈΡ Π²Π°ΠΊΡΠΈΠ½ Π½Π΅ Π²ΡΠ΅Π³Π΄Π° ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π΄ΠΎΠ±ΠΈΠ²Π°ΡΡΡΡ ΠΎΠ΄ΠΈΠ½Π°ΠΊΠΎΠ²ΠΎ ΡΡΡΠ΅ΠΊΡΠΈΠ²-Π½ΠΎΠΉ ΡΡΠΈΠΌΡΠ»ΡΡΠΈΠΈ ΠΌΠ΅ΡΡΠ½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ° Π½Π° ΡΠ»ΠΈΠ·ΠΈΡΡΡΡ
ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠ°Ρ
, Π° Π²Π°ΠΊΡΠΈΠ½Ρ, Π²Π²ΠΎΠ΄ΠΈΠΌΡΠ΅ ΡΠ΅ΡΠ΅Π· ΡΠ»ΠΈΠ·ΠΈ-ΡΡΡΠ΅ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ, ΡΠΏΠΎΡΠΎΠ±Π½Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎ ΡΡΠΈΠΌΡΠ»ΠΈΡΠΎΠ²Π°ΡΡ ΠΈΠΌΠΌΡΠ½Π½ΡΡ Π·Π°ΡΠΈΡΡ Π² ΠΎΠ±Π»Π°ΡΡΠΈ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ, Π° ΡΠ°ΠΊΠΆΠ΅
ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ°.
ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ ΡΠ΅ΡΠ΅Π· ΡΠ»ΠΈΠ·ΠΈΡΡΡΠ΅ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ Π²Π°ΠΊΡΠΈΠ½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π±Π΅Π»ΠΊΠΎΠ²ΠΎΠΉ ΠΏΡΠΈΡΠΎΠ΄Ρ ΡΡΠ΅Π±ΡΠ΅Ρ ΠΈΡΠΏΠΎΠ»Ρ-Π·ΠΎΠ²Π°Π½ΠΈΡ ΡΠΏΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΡΡ
Π°Π΄ΡΡΠ²Π°Π½ΡΠΎΠ², ΠΏΠΎΡΠΊΠΎΠ»ΡΠΊΡ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΠ΅ Π±Π΅Π»ΠΊΠΈ ΠΎΠ±ΡΡΠ½ΠΎ ΠΏΡΠΎΡΠ²Π»ΡΡΡ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΡΡ ΠΌΠΌΡΠ½ΠΎΠ³Π΅Π½Π½ΠΎΡΡΡ ΠΏΡΠΈ ΡΠ°ΠΊΠΎΠΌ ΡΠΏΠΎΡΠΎΠ±Π΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ. Π ΡΠ°Π±ΠΎΡΠ΅ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅
Π²Π°ΠΊΡΠΈΠ½Π½ΡΡ
Π°Π΄ΡΡΠ²Π°Π½ΡΠΎΠ² ΠΏΡΠΈ ΠΌΡΠΊΠΎΠ·Π°Π»ΡΠ½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΈΠ·Π°ΡΠΈΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΡΠΌΠΈ Ρ
ΠΈΠΌΠ΅ΡΠ½ΡΠΌΠΈ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΠΌΠΈ Π±Π΅Π»ΠΊΠ°ΠΌΠΈ PSPF ΠΈ PSP Π±ΡΠ»ΠΈ Π°ΠΏΡΠΎΠ±ΠΈΡΠΎΠ²Π°Π½Ρ Π΄Π²Π° ΡΡΠ°ΠΌΠΌΠ° ΠΏΡΠΎΠ±ΠΈΠΎΡΠΈΠΊΠΎΠ² β Lactobacillus rhamnosus CRL1505 ΠΈ L32. Π Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΠ΅ Ρ
ΠΈΠΌΠ΅ΡΠ½ΡΠ΅ Π±Π΅Π»ΠΊΠΈ PSPF ΠΈ PSP Π½Π΅ΡΡΡ Π² ΡΠ²ΠΎΠ΅ΠΉ ΡΡΡΡΠΊΡΡΡΠ΅ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ ΠΈΠΌΠΌΡΠ½ΠΎΠ³Π΅Π½Π½ΡΡ
ΡΠΏΠΈΡΠΎΠΏΠΎΠ² PspA, Spr1875, PsaA ΠΈ ΠΏΡΠ΅Π΄Π½Π°Π·Π½Π°ΡΠ΅Π½Ρ Π΄Π»Ρ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Streptococcus pneumoniae. ΠΠ΅Π»ΠΊΠΈ, ΠΎΡΠ»ΠΈΡΠΈΠ΅ ΠΊΠΎΡΠΎΡΡΡ
ΡΠ²ΡΠ·Π°Π½ΠΎ Ρ ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ Π² ΡΡΡΡΠΊ-ΡΡΡΠ΅ PSPF ΡΡΠ°ΡΡΠΊΠ° ΠΌΠΎΠ»Π΅ΠΊΡΠ»Ρ ΡΠ»Π°Π³Π΅Π»Π»ΠΈΠ½Π° β FliC, ΠΏΠΎ-ΡΠ°Π·Π½ΠΎΠΌΡ ΡΡΠΈΠΌΡΠ»ΠΈΡΠΎΠ²Π°Π»ΠΈ ΠΈΠΌΠΌΡΠ½Π½ΡΠΉ ΠΎΡΠ²Π΅Ρ ΠΏΡΠΈ
ΡΠΎΠ²ΠΌΠ΅ΡΡΠ½ΠΎΠΌ Π²Π²Π΅Π΄Π΅Π½ΠΈΠΈ Ρ Π΄Π²ΡΠΌΡ ΡΡΠ°ΠΌΠΌΠ°ΠΌΠΈ ΠΏΡΠΎΠ±ΠΈΠΎΡΠΈΠΊΠΎΠ². Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΠΎΠ±Π° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
ΡΡΠ°ΠΌ-ΠΌΠ° L. rhamnosus Π±ΡΠ»ΠΈ ΡΠΏΠΎΡΠΎΠ±Π½Ρ ΠΎΠΊΠ°Π·ΡΠ²Π°ΡΡ Π°Π΄ΡΡΠ²Π°Π½ΡΠ½ΡΠΉ ΡΡΡΠ΅ΠΊΡ ΠΏΡΠΈ ΠΈΠ½ΡΡΠ°Π½Π°Π·Π°Π»ΡΠ½ΠΎΠΌ Π²Π²Π΅Π΄Π΅Π½ΠΈΠΈ Π²Π°ΠΊ-ΡΠΈΠ½Π½ΡΡ
Π±Π΅Π»ΠΊΠΎΠ², ΠΏΡΠΎΡΠ²Π»ΡΠ²ΡΠΈΠΉΡΡ Π² ΡΡΠΈΠ»Π΅Π½ΠΈΠΈ ΡΠ΅ΠΊΡΠ΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΈ Π³ΡΠΌΠΎΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° Π½Π° ΡΠΎ-Π²ΠΌΠ΅ΡΡΠ½ΠΎ Π²Π²Π΅Π΄Π΅Π½Π½ΡΠΉ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΠΉ Ρ
ΠΈΠΌΠ΅ΡΠ½ΡΠΉ Π±Π΅Π»ΠΎΠΊ PSPF. ΠΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠΉ ΡΡΠΈΠΌΡΠ»ΡΡΠΈΠΈ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠΈ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
IgA Π½ΠΎΡΠΎΠ²ΡΡ
ΡΠΌΡΠ²ΠΎΠ² ΠΈ IgG ΡΡΠ²ΠΎΡΠΎΡΠΊΠΈ ΠΊΡΠΎΠ²ΠΈ Π½Π° PSP ΠΏΠΎΠ΄ Π²Π»ΠΈΡΠ½ΠΈΠ΅ΠΌ L. rhamnosus L32 Π½Π΅ ΠΏΡΠΎΠΈΡΡ
ΠΎΠ΄ΠΈΠ»ΠΎ. ΠΠ΄ΡΡΠ²Π°Π½ΡΠ½ΡΠΉ ΡΡΡΠ΅ΠΊΡ ΠΎΡ Π²Π²ΠΎΠ΄ΠΈΠΌΡΡ
Π»Π°ΠΊΡΠΎΠ±Π°ΡΠΈΠ»Π»ΡΡΠ½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΡΠ½ΠΈ-ΠΆΠ°Π»ΡΡ ΠΏΠΎΡΠ»Π΅ ΡΠ΅ΠΌΠΏΠ΅ΡΠ°ΡΡΡΠ½ΠΎΠΉ ΠΈΠ½Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ Π±Π°ΠΊΡΠ΅ΡΠΈΠΉ, ΠΎΠ΄Π½Π°ΠΊΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ
ΡΡΠ΅Π½ΠΎΠΊ L. rhamnosus CRL1505 ΠΏΡΠΎΡΠ²Π»ΡΠ» Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ. Π‘ΡΠΈΠΌΡΠ»ΡΡΠΈΡ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° Π°Π΄ΡΡΠ²Π°Π½ΡΠ°ΠΌΠΈ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΠ»Π° ΠΊ ΡΡΠΈΠ»Π΅Π½ΠΈΡ ΠΏΡΠΎΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΡΡΠ΅ΠΊΡΠ° Π²Π°ΠΊΡΠΈΠ½Ρ Π² ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Ρ
Π½Π° Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
, ΠΈΠ½ΡΠΈΡΠΈ-ΡΠΎΠ²Π°Π½Π½ΡΡ
S. pneumoniae. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π½Π΅ΠΊΠΎΡΠΎΡΡΠ΅ ΡΡΠ°ΠΌΠΌΡ Π»Π°ΠΊΡΠΎΠ±Π°ΡΠΈΠ»Π», Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ Lactobacillus rhamnosus CRL1505 ΠΈ L32, ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ Π°Π΄ΡΡΠ²Π°Π½ΡΠΎΠ² Π² ΡΠΎΡΡΠ°Π²Π΅ ΠΌΡΠΊΠΎΠ·Π°Π»ΡΠ½ΡΡ
Π²Π°ΠΊΡΠΈΠ½, ΠΎΠ΄Π½Π°ΠΊΠΎ ΡΡΠ° ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡ Π·Π°Π²ΠΈΡΠΈΡ ΠΎΡ ΡΠ²ΠΎΠΉΡΡΠ² Π²Π°ΠΊΡΠΈΠ½Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΈ ΡΠΎΡΠΌΡ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΡΠΎΠ±ΠΈΠΎΡΠΈΠΊΠΎΠ².Fil: Leontieva, G. F.. Institute of Experimental Medicine; RusiaFil: Kramskaya, T. A.. Institute of Experimental Medicine; RusiaFil: Grabovskaya, K. B.. Institute of Experimental Medicine; Rusia; RusiaFil: Filimonova, V. Yu.. Institute of Experimental Medicine; Rusia; RusiaFil: LaiΓ±o, Jonathan Emiliano. Consejo Nacional de Investigaciones CientΓficas y TΓ©cnicas. Centro CientΓfico TecnolΓ³gico Conicet - TucumΓ‘n. Centro de Referencia para Lactobacilos; ArgentinaFil: Villena, Julio Cesar. Consejo Nacional de Investigaciones CientΓficas y TΓ©cnicas. Centro CientΓfico TecnolΓ³gico Conicet - TucumΓ‘n. Centro de Referencia para Lactobacilos; ArgentinaFil: Alvarez, Gladis Susana. Consejo Nacional de Investigaciones CientΓficas y TΓ©cnicas. Centro CientΓfico TecnolΓ³gico Conicet - TucumΓ‘n. Centro de Referencia para Lactobacilos; ArgentinaFil: Danilenko, V. N.. Academy of Sciences. Institute of General Genetics. Head, Division of Fundamental Genetic Studies in Biotechnology; RusiaFil: Suvorov, A. N.. St. Peterburg State University; Rusia. Institute of Experimental Medicine. Head, Division of Molecular Microbiology; Rusi
Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study
Introduction. TheΒ standard ofΒ 1st line treatment ofΒ HER2+ metastatic breast cancer (mBC) is double blockade with trastuzumab and pertuzumab + taxane, 2nd lineΒ β Trastuzumab-emtazine. There are no standards forΒ further treatment, as well as theΒ optimal drug sequence. Expansion ofΒ theΒ arsenal ofΒ therapeutic possibilities and theΒ use ofΒ new combinations will certainly improve theΒ results ofΒ treatment ofΒ this category ofΒ patients and increase their life expectancy.Aim. We sought to describe treatment patterns ofΒ eribulinΒ and clinical outcomes ofΒ metastatic HER2-positive breast cancer treated with eribulinΒ plus trastuzumab combination inΒ academic institutions and community oncology practices across theΒ Russian Federation.Materials and methods. Patients treated with eribulinΒ anytime between Jan, 2014Β and Sep, 2019Β with aΒ diagnosis ofΒ MBC were identified by 23Β providers from Russia. Providers retrospectively reviewed theΒ health records and abstracted selected dataΒ points into an electronic case report form forΒ each eligible patient.Results. 100Β HER2-positive pts received eribulinΒ inΒ combination with trastuzumab. Median age was 55Β (31β80) yrs and ECOG status 0β3. 67% pts had visceral metastases. EribulinΒ was administered as 1st and 2nd line to 23Β (23%) pts, 3rd line to 31Β (31%) pts, 4th line and later to 46Β (46%). Median number ofΒ cycles was 5Β (2β27). ORR was 12%, SDΒ β 72%, SDΒ >Β 6Β monthsΒ β 23%, PDΒ βΒ 16%. Clinical efficacy rate achieved inΒ 35%. Median PFS was 5.07Β months (95% CI 4.021β6.119). According to theΒ ER-status theΒ response to eribulinΒ and trastuzumab was different. ORR was 18.8%, SD 72.9% inΒ pts with ER-positive MBC (nΒ =Β 48) and 5.8% and 71.2% respectively inΒ ER-negative MBC (nΒ =Β 52). Median PFS was 6.97Β months (95% CI 3.924β10.016) inΒ pts with ER-positive MBC and 4.67Β months (95% CI 3.841β5.499) inΒ ER-negative MBC (ΡΒ =Β 0.3). TheΒ combination was well tolerated: dose reductions were required inΒ 12% pts, withdrawal due to toxicity inΒ 4% pts. TheΒ most common type ofΒ toxicity was hematological with neutropeniaΒ Gr III-IV inΒ 14Β (14%) pts. Peripheral neuropathy Gr III was observed inΒ 5Β (5%) pts. No cardiotoxicity was detected.Conclusions. This is the real-life data of clinical outcomes for patients receiving eribulin plus trastuzumab for HER2-positive MBC throughout the Russian Federation. Our experience with eribulin plus trastuzumab demonstrates that this combination may be a potential effective treatment option for HER-2 positive MBC patients
Π‘ΠΠΠ‘Π’ΠΠΠΠΠ«Π ΠΠΠ«Π’ ΠΠ ΠΠΠΠΠΠΠΠ― ΠΠ ΠΠΠ£ΠΠΠΠ Π Π£Π‘ΠΠΠΠΠ―Π₯ Π ΠΠΠΠ¬ΠΠΠ ΠΠΠΠΠΠ§ΠΠ‘ΠΠΠ ΠΠ ΠΠΠ’ΠΠΠ Π. ΠΠΠ‘ΠΠΠ« Π ΠΠΠ‘ΠΠΠΠ‘ΠΠΠ ΠΠΠΠΠ‘Π’Π
Introduction. Eribulin, an non-taxane microtubule inhibitor, has been registered in Russia for patients with locally advanced or metastatic breast cancer (mBC) who received at least one chemotherapy regimen for a advanced disease, previous therapy should include anthracyclines and taxanes in adjuvant or metastatic setting, except the patients who could not be prescribed these drugs. We present our experience with eribulin in real clinical practice in Moscow and the Moscow Region.Patientsβandβmethods. We conducted a retrospective analysis of the experience with the use of eribulin in Moscow and the Moscow Region in 202 patients with mBC from January 2016 to February 2017 to assess the effectiveness and safety of the drug. All patients received previous therapy with anthracyclines and taxanes for locally advanced and / or metastatic cancer. The average age of patients at the time of inclusion in the analysis was 5 years (28β81). The status of the general condition on the ECOG 0-1 scale was registered in 81.3 % (100 / 123) of patients, the status of ECOG 2-3 in 18.7 % (23 / 123) of patients. The median of the number of courses of chemotherapy with eribulin is 4 (2β17). Patients received eribulin in 1-7 chemotherapy lines for metastatic disease. The average number of affected organs is 2 (1β5).Results. Complete response (CR) was in 3 (2 %) patients. Partial response (PR) was in 24 (15.7 %) patients, stabilization of the disease β in 89 (58. 2 %). Progression of the disease was recorded in 37 (24.1 %) patients. The median of progression-free survival (PFS) on the therapy was 4.64 (95 % CI 2.97-6.87) months. Stabilization of the disease for more than 6 months was registered in 28 (18.3 %) patients. The most significant toxicity was neutropenia and polyneuropathy (21 patients (10.4 %) and 7 patients (3.5 %), respectively).Dose reduction due to neutropenia was required by 26 patients (12.9 %). The objective response rate (ORR) depended on the chemotherapy line: in 1-3 lines the efficacy of the treatment was higher: the ORR was 21.6 %, compared to the 4th and subsequent lines β 12.3 %, respectively. With HER2-positive mBC, eribulin showed clinically significant results in combination with trastuzumab.Conclusions. Our analysis confirms that eribulin has a predictable and manageable safety profile, is an effective drug for the treatment of patients with different subtypes of mBC in a real clinical setting.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΡΠΈΠ±ΡΠ»ΠΈΠ½ β ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ ΠΌΠΈΠΊΡΠΎΡΡΡΠ±ΠΎΡΠ΅ΠΊ Π½Π΅ΡΠ°ΠΊΡΠ°Π½ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠ΄Π°, Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½ Π² Π ΠΎΡΡΠΈΠΈ Π΄Π»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΌΠ΅ΡΡΠ½ΠΎΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΌ ΠΈΠ»ΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ (ΠΌΠ ΠΠ), ΠΏΠΎΠ»ΡΡΠΈΠ²ΡΠΈΠΌ ΡΠ°Π½Π΅Π΅ Π½Π΅ ΠΌΠ΅Π½Π΅Π΅ ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΡΠ΅ΠΆΠΈΠΌΠ° Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ; ΠΏΡΠ΅Π΄ΡΠ΅ΡΡΠ²ΡΡΡΠ°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π΄ΠΎΠ»ΠΆΠ½Π° Π²ΠΊΠ»ΡΡΠ°ΡΡ Π°Π½ΡΡΠ°ΡΠΈΠΊΠ»ΠΈΠ½Ρ ΠΈ ΡΠ°ΠΊΡΠ°Π½Ρ Π² Π°Π΄ΡΡΠ²Π°Π½ΡΠ½ΠΎΠΌ ΡΠ΅ΠΆΠΈΠΌΠ΅ ΠΈΠ»ΠΈ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΠΌΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, Π·Π° ΠΈΡΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΊΠΎΡΠΎΡΡΠΌ Π½Π΅ ΠΌΠΎΠ³Π»ΠΈ Π½Π°Π·Π½Π°ΡΠ°ΡΡΡΡ Π΄Π°Π½Π½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ. Π Π½Π°ΡΡΠΎΡΡΠ΅ΠΉ ΡΠ°Π±ΠΎΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΠΉ ΠΎΠΏΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΡΠΈΠ±ΡΠ»ΠΈΠ½Π° Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΠ΅Π°Π»ΡΠ½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠΈ Π³. ΠΠΎΡΠΊΠ²Ρ ΠΈ ΠΠΎΡΠΊΠΎΠ²ΡΠΊΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ.ΠΠ°ΡΠΈΠ΅Π½ΡΡβΠΈβΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ ΡΠ΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΎΠΏΡΡΠ° ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΡΠΈΠ±ΡΠ»ΠΈΠ½Π° Π² Π³. ΠΠΎΡΠΊΠ²Π΅ ΠΈ ΠΠΎΡΠΊΠΎΠ²ΡΠΊΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ Ρ 202 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΌΠ ΠΠ Ρ ΡΠ½Π²Π°ΡΡ 2016 ΠΏΠΎ ΡΠ΅Π²ΡΠ°Π»Ρ 2017 Π³. Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°. ΠΡΠ΅ Π±ΠΎΠ»ΡΠ½ΡΠ΅ ΠΏΠΎΠ»ΡΡΠΈΠ»ΠΈ ΠΏΡΠ΅Π΄ΡΠ΅ΡΡΠ²ΡΡΡΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π°Π½ΡΡΠ°ΡΠΈΠΊΠ»ΠΈΠ½ΠΎΠ² ΠΈ ΡΠ°ΠΊΡΠ°Π½ΠΎΠ² ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ ΠΌΠ΅ΡΡΠ½ΠΎΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΠ³ΠΎ ΠΈ / ΠΈΠ»ΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°ΠΊΠ°. Π‘ΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π½Π° ΠΌΠΎΠΌΠ΅Π½Ρ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΡ Π² Π°Π½Π°Π»ΠΈΠ· ΡΠΎΡΡΠ°Π²ΠΈΠ» 58 Π»Π΅Ρ (28β81). Π‘ΡΠ°ΡΡΡ ΠΎΠ±ΡΠ΅Π³ΠΎ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΠΏΠΎ ΡΠΊΠ°Π»Π΅ ECOG 0β1 Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½ Ρ 81,3 % (100 / 123) Π±ΠΎΠ»ΡΠ½ΡΡ
, ΡΡΠ°ΡΡΡ ΠCOG 2β3 β Ρ 18,7 % (23 / 123) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΠ΅Π΄ΠΈΠ°Π½Π° ΡΠΈΡΠ»Π° ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΡΡ
ΠΊΡΡΡΠΎΠ² Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠΈΠ±ΡΠ»ΠΈΠ½ΠΎΠΌ β 4 (2β17). ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ ΡΡΠΈΠ±ΡΠ»ΠΈΠ½ Π² 1β7 Π»ΠΈΠ½ΠΈΡΡ
Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΠΌΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. Π‘ΡΠ΅Π΄Π½Π΅Π΅ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΡΡ
ΠΎΡΠ³Π°Π½ΠΎΠ² β 2 (1β5).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ.βΠΠΎΠ»Π½ΡΠ΅ ΡΠ΅Π³ΡΠ΅ΡΡΠΈΠΈ (ΠΠ ) ΠΎΡΠΌΠ΅ΡΠ΅Π½Ρ Ρ 3 (2 %) Π±ΠΎΠ»ΡΠ½ΡΡ
, ΡΠ°ΡΡΠΈΡΠ½Π°Ρ ΡΠ΅Π³ΡΠ΅ΡΡΠΈΡ (Π§Π ) β Ρ 24 (15,7 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ β Ρ 89 (58,2 %). ΠΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π·Π°ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½ΠΎ Ρ 37 (24,1 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΠ΅Π΄ΠΈΠ°Π½Π° Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ Π±Π΅Π· ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ (ΠΠΠ) Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠΈΠ±ΡΠ»ΠΈΠ½ΠΎΠΌ ΠΌΠ ΠΠ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 4,64 ΠΌΠ΅Ρ. (95 % ΠΠ 2,97β6,87). Π‘ΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π±ΠΎΠ»Π΅Π΅ 6 ΠΌΠ΅Ρ. Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½Π° Ρ 28 (18,3 %) Π±ΠΎΠ»ΡΠ½ΡΡ
. ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π·Π½Π°ΡΠΈΠΌΠΎΠΉ ΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΡΡ ΡΡΠ°Π»ΠΈ Π½Π΅ΠΉΡΡΠΎΠΏΠ΅Π½ΠΈΡ ΠΈ ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡΠΎΠΏΠ°ΡΠΈΡ (21 (10,4 %) ΠΈ 7 (3,5 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). Π Π΅Π΄ΡΠΊΡΠΈΡ Π΄ΠΎΠ·Ρ ΡΡΠΈΠ±ΡΠ»ΠΈΠ½Π° Π² ΡΠ²ΡΠ·ΠΈ Ρ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΠΌ Π½Π΅ΠΉΡΡΠΎΠΏΠ΅Π½ΠΈΠΈ ΠΏΠΎΡΡΠ΅Π±ΠΎΠ²Π°Π»Π°ΡΡ 26 (12,9 %) Π±ΠΎΠ»ΡΠ½ΡΠΌ.Π§Π°ΡΡΠΎΡΠ° ΠΎΠ±ΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° (Π§ΠΠ) ΠΏΡΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠΈΠ±ΡΠ»ΠΈΠ½ΠΎΠΌ Π·Π°Π²ΠΈΡΠ΅Π»Π° ΠΎΡ Π»ΠΈΠ½ΠΈΠΈ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ: Π² 1β3 Π»ΠΈΠ½ΠΈΡΡ
ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΡΠ»Π° Π²ΡΡΠ΅ β Π§ΠΠ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 21,6 % ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ 4-ΠΉ ΠΈ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠΈΠΌΠΈ Π»ΠΈΠ½ΠΈΡΠΌΠΈ Ρ Π§ΠΠ Π² 12,3 %. ΠΡΠΈ HER2-ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΠΌ ΠΌΠ ΠΠ ΡΡΠΈΠ±ΡΠ»ΠΈΠ½ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π» Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π»ΡΡΡΠΈΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΠΎ ΠΠΠ Π² ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Ρ ΡΡΠ°ΡΡΡΠ·ΡΠΌΠ°Π±ΠΎΠΌ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΌΠΎΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠ΅ΠΉ (ΠΌΠ΅Π΄ΠΈΠ°Π½Π° 4,64 ΠΌΠ΅Ρ. (95 % ΠΠ 2,94β6,6) ΠΈ 2,58 ΠΌΠ΅Ρ. (95 % ΠΠ 2,15β3,6) ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ).ΠΡΠ²ΠΎΠ΄Ρ.βΠΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π°Π΅Ρ, ΡΡΠΎ ΡΡΠΈΠ±ΡΠ»ΠΈΠ½, ΠΎΠ±Π»Π°Π΄Π°Ρ ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·ΡΠ΅ΠΌΡΠΌ ΠΈ ΡΠΏΡΠ°Π²Π»ΡΠ΅ΠΌΡΠΌ ΠΏΡΠΎΡΠΈΠ»Π΅ΠΌ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ, ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ Π΄Π»Ρ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ ΠΏΠΎΠ΄ΡΠΈΠΏΠ°ΠΌΠΈ ΠΌΠ ΠΠ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΠ΅Π°Π»ΡΠ½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠΈ
Combined immunization with attenuated live influenza vaccine and chimeric pneumococcal recombinant protein improves the outcome of virus-bacterial infection in mice.
Influenza and its bacterial complications are a leading cause of morbidity and mortality worldwide. The effect of combined immunization with live influenza vaccine and recombinant chimeric pneumococcal protein in dual infection caused by influenza H1N1 and S. pneumoniae (serotype 3) has been studied. The combined vaccine consisted of the strain A/California/2009/38 (H1N1) pdm and chimeric recombinant protein PSPF composed of immunodominant fragments of the surface virulence factors of S. pneumoniae-PsaA, PspA, and Shr1875-associated with modified salmonella flagellin. Vaccinated mice were infected with the influenza virus 24 hours before or 24 hours after the onset of pneumococcal infection. The protective effect of combined vaccination was shown on both models of viral-bacterial infection
Propafenone efficacy in paroxysmal atrial fibrillation
Efficacy and safety of class IΠ‘ antiarrhythmic agent, propafenone, was investigated in patients with paroxysmal atrial fibrillation (PAF), after single-dose load and during long-term preventive treatment. The study included 20 male and female patients (mean age 53,8+2,4 years). PAF was caused by coronary heart disease (CRT)) and/or essential arterial hypertension. For terminating PAF, a single dose of propafenone, 600 mg, was used. In 75% of cases, the medication was effective. In one patient (6%), long PW, wide QRS, and sinus rhythm deceleration to 48 bpm were observed. These symptoms disappeared without any additional therapy, 4 hours after sinus rhythm being restored. All patients with restored sinus rhythm received 6-month preventive treatment with propafenone (450 mg/d). In 9 patients (60%), there were no recurrent PAF episodes, in 4 (27%)Β -Β one PAF episode was registered, in 2 (13%), with BP higher than target levelsΒ -Β two PAF episodes. Extra-cardiac adverse effects of propafenone were not observed. Therefore, propafenone can be regarded as an effective and safe first-line medication for treating PAF. Long-term therapy, together with antianginal and antihypertensive treatment, significantly decreased the number of recurrent arrhythmic episodes
Immunological study and analysis of <i>E</i>. <i>faecium</i> L3 Bac +protective properties.
<p>General setup.</p
The bacterial count at different stages of GBS infection in mice after vaginal and oral vaccination.
<p>Vaginally vaccinated immune mice (n = 60, 10 mice per each point) were infected intravaginally with GBS (H36 Iac) (A). At the same time, orally vaccinated immune mice (n = 40, 10 mice per each point) were infected intraperitoneally with the same strain (B). After infection, the bacterial burden in CFU within the vaginal cavity (A) and the spleen (B) was calculated and expressed as log10. (A) Means with letter a and b differ significantly (p<0,05).(B) Means with letter c and d differ significantly (p<0,05).</p